Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.

Literature DB >> 21517811

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.

George Somlo, Ashkan Lashkari, William Bellamy, Todd M Zimmerman, Joseph M Tuscano, Margaret R O'Donnell, Ann F Mohrbacher, Stephen J Forman, Paul Frankel, Helen X Chen, James H Doroshow, David R Gandara.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21517811 PMCID： PMC3272081 DOI： 10.1111/j.1365-2141.2011.08623.x

Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998

× No keyword cloud information.

10 in total

1. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.

Authors: D Ribatti; A Vacca
Journal: Ann Hematol Date: 2003-02-27 Impact factor: 3.673

2. Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF.

Authors: V Pittini; D Teti; C Arrigo; G Aloi; M Righi
Journal: Br J Haematol Date: 2002-10 Impact factor: 6.998

3. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.

Authors: Aldo Maria Roccaro; Teru Hideshima; Noopur Raje; Shaji Kumar; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Domenico Ribatti; Beatrice Nico; Angelo Vacca; Franco Dammacco; Paul Gerard Richardson; Kenneth Carl Anderson
Journal: Cancer Res Date: 2006-01-01 Impact factor: 12.701

4. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.

Authors: Ling Lu; Faribourz Payvandi; Lei Wu; Ling-Hua Zhang; Robert J Hariri; Hon-Wah Man; Roger S Chen; George W Muller; Christopher C W Hughes; David I Stirling; Peter H Schafer; J Blake Bartlett
Journal: Microvasc Res Date: 2008-09-04 Impact factor: 3.514

Review 5. IMiDs: a novel class of immunomodulators.

Authors: Robert Knight
Journal: Semin Oncol Date: 2005-08 Impact factor: 4.929

Review 6. Cytokines and signal transduction.

Authors: Teru Hideshima; Klaus Podar; Dharminder Chauhan; Kenneth C Anderson
Journal: Best Pract Res Clin Haematol Date: 2005 Impact factor: 3.020

7. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.

Authors: Wenlin Du; Yutaka Hattori; Akinori Hashiguchi; Kensuke Kondoh; Nobumichi Hozumi; Yasuo Ikeda; Michiie Sakamoto; Jun-ichi Hata; Taketo Yamada
Journal: Pathol Int Date: 2004-05 Impact factor: 2.534

Review 8. Bevacizumab: current indications and future development for management of solid tumors.

Authors: Jenia Jenab-Wolcott; Bruce J Giantonio
Journal: Expert Opin Biol Ther Date: 2009-04 Impact factor: 4.388

9. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors: B G Durie; S E Salmon
Journal: Cancer Date: 1975-09 Impact factor: 6.860

10. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.

Authors: Michele Moschetta; Giulia Di Pietro; Roberto Ria; Antonio Gnoni; Giuseppe Mangialardi; Attilio Guarini; Paolo Ditonno; Pellegrino Musto; Fiorella D'Auria; Maria Rosaria Ricciardi; Franco Dammacco; Domenico Ribatti; Angelo Vacca
Journal: Eur J Cancer Date: 2009-11-13 Impact factor: 9.162

10 in total

12 in total

1. Emerging immune targets for the treatment of multiple myeloma.

Authors: Atif Sohail; Adeela Mushtaq; Ahmad Iftikhar; Zabih Warraich; Sandra E Kurtin; Pavan Tenneti; Ali McBride; Faiz Anwer
Journal: Immunotherapy Date: 2018-02-01 Impact factor: 4.196

2. Targeting vasculogenesis to prevent progression in multiple myeloma.

Authors: M Moschetta; Y Mishima; Y Kawano; S Manier; B Paiva; L Palomera; Y Aljawai; A Calcinotto; C Unitt; I Sahin; A Sacco; S Glavey; J Shi; M R Reagan; F Prosper; M Bellone; M Chesi; L P Bergsagel; A Vacca; A M Roccaro; I M Ghobrial
Journal: Leukemia Date: 2016-02-03 Impact factor: 11.528

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.

1. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.

2. Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF.

3. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.

4. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.

Review 5. IMiDs: a novel class of immunomodulators.

Review 6. Cytokines and signal transduction.

7. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.

Review 8. Bevacizumab: current indications and future development for management of solid tumors.

9. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

10. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.

1. Emerging immune targets for the treatment of multiple myeloma.

2. Targeting vasculogenesis to prevent progression in multiple myeloma.

3. Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα.

4. Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer.

Review 5. Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.

Review 6. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.

Review 7. Molecularly targeted therapies in multiple myeloma.

Review 8. Innovative agents in multiple myeloma.

9. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.

Review 10. Development of Novel Immunotherapies for Multiple Myeloma.